



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/86, C12Q 1/56		A1	(11) International Publication Number: WO 96/42018 (43) International Publication Date: 27 December 1996 (27.12.96)
(21) International Application Number: PCT/US96/09036		(81) Designated States: CA, JP, MX, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 6 June 1996 (06.06.96)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 08/488,510 9 June 1995 (09.06.95) US			
(71) Applicant (<i>for all designated States except US</i>): INSTRUMENTATION LABORATORY, S.P.A. [IT/IT]; Viale Monza, 338, I-20128 Milano (IT).			
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): CAMPBELL, Paula, A. [US/US]; 125 High Street, Boston, MA 02110 (US). PREDA, Luigi [-/IT]; Via Donatori di Sangue, 69, I-20050 Verano Brianza (IT).			
(74) Agent: CAMPBELL, Paula, A.; Testa, Hurwitz & Thibeault, L.L.P., High Street Tower, 125 High Street, Boston, MA 02110 (US).			

(54) Title: **THROMBOSIS RISK TEST**

(57) Abstract

The present invention provides a method for determining thrombotic risk in an individual. The method involves determining the activity of Protein C and Protein S in the plasma of the individual thought to be at thrombotic risk by adding to a plasma sample obtained from the individual: (i) a first reagent in an amount sufficient to induce or activate coagulation in the plasma, (ii) a second reagent which activates endogenous protein C in the plasma, and (iii) a third reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof. To a second plasma sample from the same subject is added a reagent which induces or activates coagulation, and a buffer or other material which does not activate protein C, and a third reagent as described above. The time, rate or both, necessary for the conversion of endogenous fibrinogen to fibrin in both the first and second samples is measured. The same steps are performed on normal control plasma, and the difference or ratio in the times, rates, or both, obtained above are determined. The difference or ratio is indicative of the thrombotic risk in the subject. A kit adapted to carry out the method also is the subject of the present invention. The methods and kits of the invention in other embodiments may comprise a first reagent comprising a synthetic substrate, a second reagent which in the first sample from the subject activates protein C, and in the second sample, a second reagent which does not activate protein C. In these embodiments, the rates of hydrolysis of the synthetic substrates are measured and compared.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

THROMBOSIS RISK TEST

Background of the Invention

The present invention relates to an analytical global test to determine the risk of thrombosis in an individual by analysis of the Protein C/Protein S functionality in said individual.

Screening tests for coagulation disorders often are used to target patients at risk for 5 bleeding. Such tests include, for example, the activated partial thromboplastin time (APTT) and the prothrombin time (PT) tests. Screening tests for coagulation disorders, or risk of bleeding, are designed to detect a significant abnormality in one or more of the clotting factors and to localize this abnormality to various steps in the coagulation pathway.

As commonly understood, coagulation may occur by two pathways, the intrinsic pathway 10 and the extrinsic pathway. The former is generally triggered by the presence of a surface, and with the presence of phospholipids and calcium, through a number of steps eventually stimulates the formation of a stabilized fibrin clot. The APTT test typically measures coagulation factors of the intrinsic pathway, where most congenital deficiencies occur, and the PT test measures coagulation factors of the extrinsic pathway.

15 The APTT test typically is performed by adding an activator such as kaolin, silica, ellagic acid, and the like with phospholipid based reagents, to plasma. This activates Factors XII and XI. Currently, in the APTT, the phospholipids employed are extracted from bovine or rabbit brain, although sources such as soy bean have been used. The exogenous phospholipids of the APTT reagent substitute for the phospholipids provided by platelets *in vivo* in the activation of Factor X 20 by Factors IX, VIII and V. Blood coagulation is limited in this clotting test by adding calcium. Factor VII is the only factor not affected by partial thromboplastin time. Thus, the APTT is normal in patients with a Factor VII deficiency.

The PT test typically is performed by adding tissue thromboplastin with calcium to plasma. This initiates clotting by activating Factor VII, which in turn activates Factor X which, in the 25 presence of Factor V, leads to the conversion of prothrombin to thrombin. The thrombin which is so produced converts fibrinogen to fibrin. The PT test therefore bypasses the intrinsic clotting pathway and is normal in patients with deficiencies of Factors XII, XI, IX, and VIII. PT is

abnormal in patients with deficiencies of Factors VII, X, V, prothrombin or fibrinogen. Tissue thromboplastin is a phospholipid extract (e.g., from rabbit brain or lung or human brain or placenta) to which calcium has been added.

5 Protein C and Protein S (PC and PS, respectively) also are involved in the coagulation process. Protein C is a double-chained, vitamin K-dependent glycoprotein in plasma which is synthesized in the liver. A physiologically indifferent coagulation precursor (decarboxyprotein C) is thereby first formed. Carboxylation of γ -glutamic acid residues in the protein by a vitamin K-dependent carboxylate results in the formation of protein C. Protein C itself is a pro-enzyme and is converted by thrombin into activated protein C (aPC). The latter acts as an anti-coagulant by a 10 proteolytic inactivation of the activated coagulation Factors V and VIII. The inhibitory action of the active Protein C is increased by a cofactor, Protein S. Protein S is a single-chained glycoprotein in plasma which is also vitamin K-dependent. Active protein C and protein S form an equimolar complex. A lowered protein C level, as well as protein S level, have been described in patients with liver diseases, disseminated intravascular coagulation (DIC) and after oral 15 anticoagulant therapy. A congenital deficiency of protein C or of protein S results in an increased venous thromboembolic risk. Therefore, protein C, as well as protein S, play an important part not only in the case of physiological haemostasis, but also in many diseases, and, especially in the case of thrombosis.

20 In commercially available test processes, the amount of protein C in plasma is determined by enzyme-labelled antibodies. However, this process suffers from the disadvantage that the antibodies used for the determination also react with the above mentioned decarboxyprotein C. Since the plasma concentration of decarboxyprotein C frequently increases very considerably during the course of a treatment with anticoagulants, this process involves a large source of error which, under certain circumstances, can result in false or insufficient therapy.

25 For example, in some photometric methods, Protein C is activated using Protac[®] (available from Pentapharm, Switzerland), which is obtained from the venom of the snake *Agkistrodon contortrix contortrix*, together with a chromogenic protein C substrate. In this process, the preparation of the sample can be omitted, however, it is not possible to differentiate between carboxylated and non-carboxylated protein C. It is known that only carboxylated protein 30 C is effective *in vivo*. Therefore, no information about the biological activity of the protein C molecule can be obtained with this process.

- 3 -

The amount of protein S in a plasma can be determined by an immuno-radiometric test, such as that described, for example, by Bertina et al. (Thromb Haemostas., 52 (2), 268-272 (1985). This process, however, suffers from the disadvantage that the antibodies used for the determination also react with nonfunctional protein S, for example with decarboxyprotein S or 5 with protein S complexed with C₄-binding protein. Under certain circumstances, this results in falsely positive protein S values. The authors also describe a potential method for determining protein S in plasma in which activated protein C is admixed with human plasma and the partial thromboplastin time (PTT) is determined. The length of the PTT is indicative of the concentration of functional protein S. The reaction can be identified by the cleavage of fibrinogen 10 by thrombin and the formation of a fibrin clot. However, the detection processes are limited, protein C and protein S cannot be simultaneously determined, and purified activated protein C must be used.

Thus, there is a need for a rapid, global test for determining the thrombotic risk in a subject by surveying the activity of all factors, known or unknown on the biochemical mechanisms 15 of coagulation.

Summary of the Invention

The present invention is directed to an analytical global test for determining the thrombotic risk of a subject by the exploration of protein C/protein S functionality. Additional features and advantages of the invention will be set forth in the description which follows, and in 5 part will be apparent from the description, or may be learned by practice of the invention. The objectives and other advantages of the invention will be realized and attained by the methods and kits particularly pointed out in the written description and claims hereof.

To achieve these and other advantages, and in accordance with the purpose of the invention, as embodied and broadly described herein, the invention provides a method for 10 determining thrombotic risk in a subject by adding to a plasma sample obtained from the subject (i) a first reagent in an amount sufficient to induce or activate coagulation in the plasma, (ii) a second reagent which activates endogenous protein C in the plasma, and (iii) a third reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof.

One then adds to a second plasma sample from the same subject (i) a reagent which 15 induces or activates coagulation, (ii) a buffer or other material which does not activate protein C, and (iii) a third reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof. The time, rate, or both, necessary for the conversion of endogenous fibrinogen to fibrin in both the first and second samples is measured. The same steps are performed on normal control plasma, and the difference or ratio in the times, rates, or both, 20 obtained above are determined.

In other embodiments, the methods of the invention comprise adding to a plasma sample obtained from the subject a synthetic substrate, and a second reagent which activates protein C in the plasma; and to a second sample from the same subject adding a synthetic substrate and a second reagent which does not activate protein C in the plasma. The rates of hydrolysis of the 25 synthetic substrates in each sample are then measured, and compared as above. The same steps are performed on normal control plasma, and the rates of hydrolysis are determined.

In some embodiments, the first reagent is selected from the group consisting of, but not limited to, Factor IXa, reagents which generate Factor IXa *in vitro*, and APTT reagents. In other embodiments, the first reagent is selected from the group consisting of Factor Xa, reagents 30 which generate Factor Xa *in vitro*, PT reagents, and activators of the extrinsic coagulation pathway.

- 5 -

Preferred second reagents may be a purified fraction of venom obtained from a venom producing organism, such as an arachnid or a reptile, i.e., snake or spider venom. In the currently preferred embodiment, the second reagent is a snake venom fraction obtained from *Agkistrodon contortrix contortrix*. In other embodiments, the second reagent may be a recombinant venom 5 protein or polypeptide.

A kit for determining the thrombotic risk in a subject also is the subject of the present invention. In one embodiment, the kit comprises a first container which has (i) a first reagent in an amount sufficient to induce or activate coagulation in a plasma sample obtained from the subject, (ii) a second reagent which activates endogenous protein C in the plasma, and (iii) a third 10 reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof.

The kit of the invention further comprises a second container for adding to a second plasma sample from the same subject a first reagent which activates or induces coagulation; a buffer or other material which does not activate protein C; and calcium salts, phospholipids or 15 tissue thromboplastin, or a combination thereof.

In some embodiments, the kit comprises at least one container having therein a first reagent comprising a synthetic substrate, and a second reagent which activates protein C; and at least one second container having therein a first reagent comprising a synthetic substrate, and a second reagent comprising a buffer or other material which does not activate protein C. It is 20 understood that the first and second reagents may be combined in a single container (e.g., a vial) or may be provided in separate containers.

The kit may contain first reagents selected from the group consisting of Factor IXa, reagents which generate Factor IXa *in vitro* and APTT reagents. Alternatively, the first reagent may be selected from the group consisting of Factor Xa, reagents which generate factor Xa *in* 25 *vitro*, PT reagents, and activators of the extrinsic coagulation pathway.

In preferred embodiments, the second reagent comprises a purified fraction of venom obtained from a venom producing organism, such as an arachnid or snake. In a currently preferred embodiment, the second reagent is a purified snake venom fraction obtained from *Agkistrodon contortrix contortrix*. The second reagent also may be a recombinant venom protein 30 or polypeptide.

- 6 -

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed.

The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate one embodiment of the invention and together with the description serves to explain the principles of the invention.

- 7 -

Brief Description of the Drawings

The Figure is a calibration curve for the calculation of the coagulative activity, as measured in Equivalent Units of Protein C (EUC), assuming that normal plasma has an activity of 100 % EUC, and a plasma deficient in protein C has an activity of 0 % EUC.

Detailed Description of the Invention

The present invention relates to an analytical global test useful for the exploration of protein C/protein S functionality. The global test can be a diagnostic aid for the evaluation of thrombotic risk in patients suffering from hereditary and non-hereditary thrombophilia (i.e., 5 disorders of the hemopoietic systems in which there is a tendency toward the occurrence of thrombosis), or otherwise in patients undergoing particularly pharmacologic treatments such as extroprogesterinics, etc. Additionally, patients undergoing surgery can be evaluated to determine thrombotic risk.

The claimed invention is an analytical *in vitro* test that can be used to diagnose clotting 10 anomalies involved in the inhibitory system, due to either PC deficiency, PS deficiency, or to the presence of molecular anomalies of Factor Va, or to the presence of anti-aPC antibodies. Generally, the methods of the invention provide that patient plasma is incubated with an 15 exogenous reagent able to activate or induce clotting activity; an exogenous reagent that transforms endogenous PC to aPC, and other components such as calcium salts, phospholipids or tissue thromboplastin necessary to complete the clotting reaction. To a second sample of plasma from the same patient is added the first reagent, the third reagent, and in lieu of the second reagent, a substance which does not activate PC, thus showing the patient's global clotting activity. The same steps are repeated using a normal plasma control sample.

The times or rates necessary for the conversion of fibrinogen into fibrin are measured for 20 both samples, and the ratio or difference between the non-activated sample and the activated sample is determined. The ratio or difference is indicative of the presence of potential thrombotic risk. As an example, if the difference in time of the patient plasma sample is shorter than the normal control sample, then there is a high risk of a thrombotic event. The methods and kits of the invention are discussed in further detail below.

25 The analytical test provides a method for determining the ratio between the clotting activity and the inhibitory activity of the protein C/ protein S system in a plasma sample. In one embodiment, the test involves first adding to a plasma sample from the subject a first reagent sufficient to induce or activate coagulation in the plasma. Any reagent capable of inducing or activating coagulation can be used. Preferred first reagents include, but are not limited to, Factor 30 IXa, reagents which generate Factor IXa *in vitro*, APTT reagents, Factor Xa, reagents which generate Factor Xa *in vitro*, PT reagents and activators of the extrinsic coagulation pathway.

Activators of the extrinsic coagulation pathway may be any activators having the desired activity. Specifically, activators useful in the invention may include natural sourced or recombinant tissue thromboplastins, including, for example, bovine thromboplastin, human thromboplastin, rabbit thromboplastin and porcine thromboplastin. Bovine thromboplastin 5 currently is preferred. Portions of such activators may also have the desired activity. A recombinant or synthetic mutant or modified thromboplastin having the desired activity also may be used for this purpose. Mutant or modified thromboplastins are recombinant or synthetic proteins in which a portion of the nucleotide sequence encoding the protein or the amino acid sequence is missing or altered, but which retains thromboplastin activity. One skilled in the art 10 may readily identify other activators of the extrinsic coagulation pathway which would be useful in the claimed invention.

A second reagent also is added to the plasma sample obtained from the subject. The second reagent activates endogenous Protein C in the plasma. The second reagent can be any substance having the desired activity. For example, one may obtain the second reagent from the 15 venom of venom producing organisms such as arachnids or reptiles. For example, snake venoms from which the desired fraction can be purified may be obtained from *Agistrodon contortrix* *contortrix*, *A.C. mokasen*, *A.C. pictigaster*, *A. piscivours*, *A. ieucostoma*, *A. bilineatus*, *Bothrops moojeni*, *B. pradoi*, *Cerastes cerastes*, *Vipera lebetrina* or *V. russelli*. Preferably, the second 20 reagent is snake venom, most preferably a fraction obtained from *Agkistrodon contortrix* *contortrix*. Such a reagent is commercially available under the tradename Protac.® The second reagent may, in some instances, be a derivatized or modified form of the venom, or in other embodiments at least a portion of a recombinant venom protein or polypeptide having the desired activity.

The third reagent added to the plasma sample may comprise calcium salts, phospholipids 25 or tissue thromboplastin, or any combination thereof.

A second sample obtained from the same subject is combined with the first reagent which activates coagulation, a buffer or other material which does not activate Protein C, and the third reagent, e.g., calcium salts, phospholipids, or tissue thromboplastin or any combination thereof.

One then measures the conversion of endogenous fibrinogen to fibrin in both the first sample and 30 the second sample. The measurements may, for example, determine the rate of conversion, the time of conversion, or both. One skilled in the art can easily select which measurements best suits

- 10 -

each individual application. If the third reagent is a synthetic substrate, the hydrolysis of the substrate is measured instead of the conversion of fibrinogen to fibrin.

5 The rate or time of conversion of fibrinogen to fibrin can be measured by methods known in the art for determining coagulation times or rates, such as, for example, by measuring the change in optical density of the sample.

10 The difference or ratio between the measurements of the rate or time (or both) obtained above is then calculated, and the identical steps performed on normal control plasma. Then, one determines the difference or ratio 1) in the times, rates (or both) obtained for the normal control; and 2) the first and second samples. The difference is indicative of the thrombotic risk in the subject. If the time, rate, or both, calculated for the test plasma is shorter than the time, rate or both for the normal control plasma, the patient is at increased thrombotic risk.

15 Specifically, shorter conversion times or rates are indicative of a deficiency in Protein C, Protein S, or both. Lowered or reduced levels of Protein C or Protein S may result in an increased risk of clot formation. Alternatively, a high level of PC or PS will indicate a normal coagulation pattern, and thus, a low risk of thrombosis.

20 In other embodiments, the methods of the invention comprise adding to a first sample from the subject a synthetic substrate, and a second reagent which activates protein C. The second sample from the subject is combined with a synthetic substrate and a second reagent which does not activate protein C. In these embodiments, the rate of hydrolysis of the synthetic substrate in the first and second samples are measured and compared.

25 The synthetic substrate, may, for example be a thrombin substrate, useful for monitoring the reaction. Thrombin substrates may include synthetic fibrinogen or portion thereof, or other protein or polypeptide which can be converted by thrombin to a detectable substance. The synthetic substrate may comprise a label or tag such that the rate of hydrolysis of the substrate may be measured. It is contemplated that the label or tag be intrinsic to the substrate, or a detectable moiety attached to the substrate.

30 The methods of the invention may be carried out manually, or automatically. The methods preferably are carried out automatically using a specially designed instrument, such as those available from Instrumentation Laboratory, S.p.A., Milan, Italy. The samples are loaded into the instrument, and reagents are added, and the conversion times or rates are determined in accordance with the manufacturer's instructions.

The claimed invention also encompasses kits for determining thrombotic risk in a subject. The kits contain a first container having (i) a first reagent in an amount sufficient to induce or activate coagulation in a plasma sample obtained from the subject, (ii) a second reagent which activates endogenous Protein C in the plasma, and (iii) a third reagent comprising calcium salts, 5 phospholipids or tissue thromboplastin, or a combination thereof. The term "container" as used herein means any container capable of housing the reagents listed above. In various embodiments, the first container may comprise a separate vial for each reagent, a single vial with all three reagents, or, two vials containing any combination of the three reagents. One skilled in the art may choose any configuration for the first container, based upon the particular application 10 and convenience of use. The container may optionally be a disposable, single use container, or, in other embodiments, may be a container capable of sterilization and reuse.

The kit of the invention also has a second container for adding to a second plasma sample from the same subject (i) a first reagent, (ii) a buffer or other material which does not activate Protein C, and (iii) a third reagent comprising calcium salts, phospholipids or tissue 15 thromboplastin, or a combination thereof.

The reagents used in the kits may be the same reagents as discussed above in relation to the methods of the invention.

In some embodiments, the kits of the invention have a first container comprising a synthetic substrate and a second reagent which activates protein C. The second container 20 comprises a synthetic substrate and a buffer or material which does not activate protein C. In other embodiments the kits of the invention may contain only one container, i.e., either the first or the second container.

Thus, as described above, the claimed invention allows the rapid evaluation of the functionality of PC and PS in subjects. The tests of the invention can be a valid diagnostic aid for 25 screening patient samples to recognize those patients with high thrombotic risk, i.e., hereditary PC deficiency, heterozygous or homozygous mutations, such as F.V. Leiden mutation, and patients undergoing surgery. The methods of the invention encompass a global test because they are capable of detecting the influence of other factors, known or unknown, in addition to PC and PS, 30 on the biochemical mechanism that allows effective activated PC inhibiting action on the physiological substrates (i.e., Factors Va and VIIIa).

- 12 -

The global activity of the system may be measured in equivalent units of protein C, arbitrarily assigning an activity value of 100% to a pool of normal patient plasma and 0% to a PC deficient plasma. Other means of measurement may be used to obtain the relative activity of the PC/PS system, and are easily determined by the skilled artisan.

5

EXAMPLES

Example 1

The analytical test below can be carried out either manually or automatically. The volumes reported below were obtained using the Research Program of the ACL 3000/p system (available from Instrumentation Laboratory, S.p.A., Milan, Italy).

10 50 μ L of undiluted patient plasma were separately loaded in a rotor with 50 μ L of H₂O (or similar buffer), and centrifuged. After 150 seconds, 50 μ L of calcium bovine thromboplastin was added. The coagulation reaction was allowed to proceed for 240 seconds, and the coagulation time was calculated using the principles of the ACL. The measured coagulation time, or rate (To) represents the coagulative activity of the plasma sample.

15 In a second rotor, another sample from the same subject was processed as above, except that the H₂O is replaced with a PROTACTM solution (fractionated *Agkistrodon contortrix contortrix* venom, 0.125 U/mL conc.). The coagulation time, or rate (Ta) was then measured.

The ratio of (Ta/To) or the difference (Ta-To) represents an index of the total functionality of the PC-PS inhibitor system.

20 As an example, the values given below were obtained by the method described in the example above, and represent the To, Ta, and % E.U.C. of patients with a deficiency of PC, PS or with an increased aPC resistance. The % E.U.C. for normal plasma is between 57 and 153.

<u>Defect</u>	<u>To</u>	<u>Ta</u>	<u>% E.U.C.</u>
PC deficiency	45.6	84.0	43
	39.4	66.0	39
PS deficiency	49.2	50.0	1
	49.0	58.0	13
aPC resistance	32.8	37.2	4
	30.2	34.2	12

- 13 -

Example 2

MATERIALS AND METHODS

Collection of Blood Samples

Blood samples (20 ml) were collected by venipuncture with 21-gauge butterfly infusion sets into plastic syringes containing 3.8% (wt/vol) sodium citrate in a ratio of 0.1:0.9 (vol/vol) anticoagulant to blood. Platelet poor plasma was obtained by centrifugation at 2000 x g for 20 minutes and stored at -80°C until it was analyzed.

Routine coagulation assays

Laboratory investigations including the measurement of activated-partial thromboplastin time (aPTT) and prothrombin time (PT), assays for antithrombin III and plasminogen, PC antigen and activity, total and free PS antigen and PS activity, have been performed as previously described. Giolami et al., Br. J. Haematol. 85:521-526 (1993); Giolami et al., Thromb. Haemost., 61:144-147 (1989); Preda et al., Thromb. Res., 60:19-32 (1990).

A reference pool of normal plasma for all these assays was obtained from 40 healthy subjects of both sexes, aged 20 to 60 years. Normal values for each test were determined in 80 healthy individuals of both sexes, aged 20 to 70 years.

The criteria used for the classification of AT III, PC and PS defects were in accordance with those reported in the current literature. Dahlback, Thromb. Haemost., 74:139-148 (1995); Alach et al., Thromb. Haemost., 74:81-89 (1995).

Evaluation of the response to APC in plasma (APC resistance test). The test was performed on an ACL 3000plus/R (Instrumentation Laboratory, S.p.A., Milan, Italy) using a modification of the methods proposed by Bertina et al. (Nature, 369:64-67 (1994); Thromb. Haemost., 72:880-886 (1994)). Briefly, fifty microliters of undiluted plasma were incubated with 50 ul of aPTT-lyophilized silica (Instrumentation Laboratory, S.p.A., Milan, Italy) for 300 seconds at 37°C. Clot formation was started either by addition of 50 ul of 25 mM calcium-chloride, 25 mM Tris-HCl (pH 7.5), 50 mM NaCl and 0.05% ovalbumin (aPTT-APC) or by 50 ul of the same reagent containing also 1.0 ug/ml (final concentration) of human APC (Enzyme Research Laboratory, South Bend, Indiana, USA) (aPTT+APC). An "APC sensitivity ratio" (APC-SR) was calculated dividing the aPTT+APC (seconds) by the aPTT-APC (seconds). The APC-SR was then normalized (n-APC-SR) to the ratio obtained with a reference plasma. Resistance to APC is

- 14 -

defined by n-APC-SR less than 0.80. A n-APC-SR between 0.45 and 0.70 was consistent with the presence of heterozygous F.V Leiden mutation whereas the diagnosis of homozygous defect was made if the n-APC-SR was < 0.45.

DNA analysis for F.V Leiden mutation. High molecular weight DNA was extracted from 5 $5 \mu\text{l}$ of peripheral blood using a binding matrix (Biorad Lab, Hercules, CA, USA). DNA analysis was performed as previously described. Bertina et al., Nature, 369:64-67 (1994); Simoni et al., Stroke, 26:885-890 (1995).

PC-PS system global test

This test consists of the measurement of the PT of a plasma sample before the activation 10 (PTo) and after the activation of the native PC (PTa) present in the sample by PROTAC®, a snake venom derived from *Agkistrodon Contortrix Contortrix* obtained from Pentapharm (Basel, Switzerland).

The prolongation of the clotting time (PTa-PTo) after activation of the native PC reflects 15 the global activity of the PC-PS system. The global activity of the PC-PS system is expressed as the percentage of Equivalent Unit of PC (EUC%). Therefore PTa-PTo obtained in a pooled normal plasma corresponded to 100 EUC whereas that obtained in PC deficient plasma was consistent with 0 EUC. A calibration curve was obtained by diluting pooled normal plasma (PNP) in PC deficient plasma.

The test was carried out in a two step cycle, using the ACL 3000plus/R coagulometer, at 20 the following analytical conditions:

sample	50 μl
reagent 1	50 μl
reagent 2	50 μl
activation time	150 sec
inter-ramp interval	3 sec
delay time	10 sec
acquisition time	240 sec
speed	1200 rpm

- 15 -

Clotting time was calculated using the following elaboration path:

Mode	S/Rx100
Data	Sm1=15, Sm2=11
First derivative	Calc=3, Sm1=11
Criterion	1st derivative

As mentioned above, the PC-PS system global test consists of a double PT. Reagent 1 was H₂O and PROTAC® at a final concentration of 0.125 U/ml, in the basal PT and in PT performed after activation of native PC, respectively. Reagent 2 was a bovine thromboplastin (Instrumentation Laboratory, S.p.A., Milan, Italy), containing 20 mM Ca-ion and polybrane as a heparin inhibitor.

EUC% was calculated as follows:

$$\text{EUC\%} = \frac{(\text{PTa} - \text{PTo})_{\text{sample}}}{10} \times 100$$

As normal plasma we used a dried plasma (Calibration plasma, lot #N0743187, (Instrumentation Laboratory, S.p.A., Milan, Italy) in which the activities of all clotting factors were > 90%, while PC and PS functional activities were 90% and 98% respectively.

Statistical analysis. Differences between the groups were evaluated by a non-parametric test (unpaired Wilcoxon test) and p values > 0.05 were not considered significant (NS).

RESULTS

The evaluation of PC/PS system activity was performed in 231 plasma samples. One hundred and twelve belonged to normal individuals (control group), 36 to patients with PC deficiency, 22 with PS deficiency, 35 with aPC resistance due to F.V Leiden mutation and 26 with thrombophilia due to other coagulation disorders (2 with ATIII deficiency, 1 with HC II deficiency, 1 with plasminogen deficiency and 12 other with hyperhomocystinemia). Table 1 shows the dose-response curve for the test. When the prolongation of the clotting time (Ta-To) was plotted against the percentage of EUC, a linear correlation was obtained.

- 16 -

Table 1

DOSE-RESPONSE CURVE			
EUC	To	Ta	Ta-To
%	sec	sec	sec
100	40,4	134,7	105,0
60	41,0	96,5	62,9
40	42,3	77,5	40,4
20	42,4	58,0	18,2
10	42,4	49,0	8,0
0	42,7	40,7	-1,0

Table 2 shows the data of the intra and inter-assay coefficient of variation (CV%) of the global test, determined for three levels of EUC% corresponding to a calibration plasma (NP #NO743187), a control plasma containing 40% PS and a control plasma containing 20% PC. The 5 assay precision gave satisfactory results.

Table 2

	NP #NO743187	PS control 40%	PC control 20%
EUC % average	103,0	13,1	15,2
CV % intra-	1,5-6,5	1,3-6,8	1,4-7,5
inter-	4,6	6,5	6,7

Table 3 contains the data of the control group as well as those of four patient groups. Shown are the number of samples according to their deficiency status, mean EUC% values, median EUC% values, number of samples for which the EUC% levels were in agreement with the 10 deficiency status.

- 17 -

Table 3

	N°	EUC %		N°
		average \pm 1 std	median	
Normal control	112	96,0 \pm 25,3	93,5	103
PC defect	36	50,8 \pm 18,2	41,0	33
PS defect	22	32,4 \pm 28,7	24,5	20
aPC-resistant	35	26,2 \pm 13,9	25,0	34
Other	26	95,6 \pm 31,9	83,5	26
TOTAL	231			

The present test showed a high sensitivity for the deficiency of the two principal inhibitors, PC (33/36, 91.7%) and PS (20/22, 90.9%) as well as for F.V Leiden mutation (34/35, 97.1%). Out of 112 individuals of the control group, 103 (92%) were identified as normal by the global 5 activity test. All other patients with defects different from those of the PC/PS system had a normal global test (26/26, 100%).

In the PC/PS global test unfractionated heparin was tolerated up to a concentration of 0.4 U/ml.

Genetic defects of PC, PS, AT considered together, are found in only 5-10% of patients

10 presenting with familial venous thrombophilia. In about 90% of cases, APC-resistance is caused by a single point mutation in the F.V gene predicting the replacement of Arg506 with Gln.

Bertina et al., Nature, 369:64-67 (1994). Depending on the selection of patients taken into account, F.V Leiden was found in about 20-50% of cases of thrombophilia. Defects involving the PC/PS system are nowadays the most frequent cause of inherited thrombophilia. Impairment of 15 the PC/PS system due to the presence of antiphospholipid antibodies is maintained to be a pathogenetic mechanism of thrombosis in some cases.

As shown by the results obtained above, the sensitivity of the test of the invention in the detection of PC and PS defects was high. Only three patients out of 36 with PC deficiency went undetected, 2 out of 22 with PS deficiency and only 1 out of 35 with F.V. Leiden mutation. Nine

20 patients belonging to the control group exhibited an abnormal response to the PC/PS global test.

No PC or PS defects or APC resistance was found in these individuals. The presence of antiphospholipid antibodies also was excluded. None of the other 26 patients with thrombophilia

- 18 -

due to other genetic defects showed abnormal PC/PS global activity. Native PC in the PC/PS global activity test is activated by PROTAC®, therefore, it is likely that impairment of physiological activation of PC by thrombin-thrombomodulin complex cannot be detected by this assay.

5 The present method may be usefully employed as a screening-test in the daily screening of subjects with increased thrombotic risk related to the reduction of the global activity of the PC-PS system.

It will be apparent to those skilled in the art that various modifications and variations can be made in the kits and methods of the present invention without departing from the spirit or 10 scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided that they come within the scope of the appended claims and their equivalents.

- 19 -

CLAIMS

What is claimed is:

- 1 1. A method for determining thrombotic risk in a subject, said method comprising:
 - 2 a. adding to a plasma sample obtained from said subject (i) a first reagent in an amount sufficient to induce or activate coagulation in the plasma, (ii) a second reagent which activates endogenous Protein C in the plasma, and (iii) a third reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof;
 - 6 b. adding to a second plasma sample from the same said subject (i) a first reagent which activates or induces coagulation, (ii) a buffer or other material which does not activate protein C, and (iii) a third reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination thereof;
 - 10 c. measuring the time, rate, or both, necessary for conversion of endogenous fibrinogen to fibrin in the sample of step (a);
 - 12 d. measuring the time, rate, or both necessary for conversion of endogenous fibrinogen to fibrin in the plasma sample of step (b);
 - 14 e. calculating the difference or ratio between the times, rates or both, obtained in steps (c) or (d);
 - 16 f. performing steps (a), (b), (c) and (d) on a sample of normal control plasma; and
 - 17 g. determining the difference or ratio in the times, rates, or both, obtained in steps (e) and (f) wherein said difference is indicative of the thrombotic risk in said subject.
- 1 2. A method for determining thrombotic risk in a subject, said method comprising
 - 2 a) adding to a plasma sample obtained from said subject (i) a first reagent comprising a synthetic substrate, and (ii) a second reagent which activates endogenous Protein C in the plasma;

- 20 -

5 - b) adding to a second plasma sample from the same said subject (i) a first reagent
6 comprising a synthetic substrate, and (ii) a buffer or other material which does not activate
7 Protein C;

8 c) measuring the rate of hydrolysis of the synthetic substrate in the sample of step (a);
9 d) measuring the rate of hydrolysis of the synthetic substrate in the sample of step (b);
10 e) calculating the difference between the rates obtained in steps (c) and (d);
11 f) performing steps (a), (b), (c), and (d) on a sample of normal control plasma; and
12 g) determining the difference or ratio in the rates obtained in steps (e) and (f) wherein
13 said difference is indicative of the thrombotic risk in said subject

1 3. The method of claim 1 wherein said first reagent is selected from the group consisting of
2 Factor IXa, reagents which generate Factor IXa *in vitro* and APTT reagent.

1 4. The method of claim 1 wherein the first reagent is selected from the group consisting of
2 Factor Xa, reagents which generate Factor Xa *in vitro*, PT reagents, and activators of the
3 extrinsic coagulation pathway.

1 5. The method of claim 1 or 2 wherein said second reagent comprises a purified fraction of
2 venom obtained from a venom producing organism

1 6. The method of claim 5 wherein the venom is snake venom obtained from
2 *Agkistrodon contortrix contortrix*.

1 7. The method of claim 1 or 2 wherein the second reagent comprises at least a portion of a
2 recombinant venom protein.

1 8. A kit for determining thrombotic risk in a subject, said kit comprising:
2 a. a first container comprising: (i) a first reagent in an amount sufficient to induce or
3 activate coagulation in a plasma sample obtained from said subject, (ii) a second reagent which

- 21 -

4 activates endogenous Protein C in the plasma, and (iii) a third reagent comprising calcium salts,
5 phospholipids or tissue thromboplastin, or a combination thereof;

6 b. a second container for adding to a second plasma sample from said same subject

7 (i) said first reagent, (ii) a buffer or other material which does not activate Protein C, (iii) a third
8 reagent comprising calcium salts, phospholipids or tissue thromboplastin, or a combination
9 thereof.

1 9. A kit for determining thrombotic risk in a subject, said kit comprising:

2 a) a first container comprising (i) a first reagent comprising a synthetic substrate, and
3 (ii) a second reagent which activates endogenous Protein C in the plasma;

4 b) a second container for adding to a second plasma sample from the same said subject
5 (i) said first reagent comprising a synthetic substrate, and, (ii) a buffer or other material which
6 does not activate Protein C

1 10. The kit of claim 8 wherein said first reagent is selected from the group consisting of
2 Factor IXa, reagents which generate Factor IXa *in vitro* and APTT reagents.

1 11. The kit of claim 8 wherein the first reagent is selected from the group consisting of
2 Factor Xa, reagents which generate Factor Xa *in vitro*, PT reagents and activators of the
3 extrinsic coagulation pathway.

1 12. The kit of claim 8 or 9 wherein said second reagent comprises a purified fraction of
2 venom obtained from a venom producing organism.

1 13. The kit of claim 12 wherein the venom is snake venom obtained from
2 *Agkistrodon contortrix contortrix*.

1 14. The kit of claim 8 or 9 wherein the second reagent comprises a recombinant venom
2 protein.


1/1

C.U.C. %	Ta SEC	To SEC	Ta SEC
0	-2.0	40.4	33.4
15	6.6	40.2	46.8
30	21.2	40.8	62.0
60	53.8	40.6	94.4
100	98.8	38.4	137.2

y - INTERCEPT = 6.68
SLOPE = 0.962

$r^2 = 0.994$

CALIBRATION CURVE



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/09036

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/86 C12Q1/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 10261 (B. DAHLBÄCK) 27 May 1993 see the whole document ---	1-14
X	EP,A,0 434 377 (ORTHO DIAGNOSTICS SYSTEMS INC.) 26 June 1991 see the whole document ---	1
Y	EP,A,0 406 971 (INSTRUMENTATION LABORATORY S.P.A.) 9 January 1991 see the whole document ---	2-14
Y	EP,A,0 236 985 (BOEHRINGER MANNHEIM GMBH.) 16 September 1987 see the whole document ---	2-14
Y	EP,A,0 445 626 (BEHRINGWERKE AKTIENGESELLSCHAFT) 11 September 1991 see the whole document ---	2-14
	-/-	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

6 November 1996

26.11.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Griffith, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/09036

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 633 473 (STIFTUNG FÜR DIAGNOSTISCHE FORSCHUNG) 11 January 1995 see the whole document -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/09036

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9310261	27-05-93	SE-B- AT-T- AU-B- AU-A- CA-A- DE-D- DE-T- DE-T- EP-A- ES-T- JP-T- SE-A- US-A-	470274 132909 666484 2198092 2119761 69207607 69207607 608235 0608235 2081618 7501217 9103332 5443960	20-12-93 15-01-96 15-02-96 15-06-93 27-05-93 22-02-96 20-06-96 22-12-94 03-08-94 01-03-96 09-02-95 14-05-93 22-08-95
EP-A-434377	26-06-91	US-A- AT-T- CA-A- DE-D- DE-T- ES-T- GR-B-	5169786 126894 2032561 69021849 69021849 2088992 1001222	08-12-92 15-09-95 20-06-91 28-09-95 21-12-95 01-10-96 21-06-93
EP-A-406971	09-01-91	CA-A- DE-D- DE-T- ES-T- JP-A- JP-B- US-A-	2019872 69016858 69016858 2068325 3216199 7040959 5147805	08-01-91 23-03-95 08-06-95 16-04-95 24-09-91 10-05-95 15-09-92
EP-A-236985	16-09-87	DE-A- AU-B- AU-A- CA-A- DE-A- DK-B- ES-T- JP-C- JP-B- JP-A-	3607559 577975 6978587 1299075 3780485 171086 2043612 1786173 4076629 62212569	10-09-87 06-10-88 10-09-87 21-04-92 27-08-92 28-05-96 01-01-94 31-08-93 04-12-92 18-09-87

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/09036

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-236985		US-A-	5001069	19-03-91
EP-A-445626	11-09-91	DE-A-	4006634	05-09-91
		AU-B-	652737	08-09-94
		CA-A-	2037434	04-09-91
		JP-A-	4350560	04-12-92
EP-A-633473	11-01-95	JP-A-	7151763	16-06-95
		US-A-	5506146	09-04-96

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.